Brief: Tiziana Announces Positive Qualitative Six-Month Pet Scan Results
13/10/2023 12:05
Oct 13 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA ANNOUNCES POSITIVE QUALITATIVE SIX-MONTH PET SCAN
RESULTS WITH INTRANASAL FORALUMAB TREATING MULTIPLE SCLEROSIS
PATIENTS DIAGNOSED WITH NON-ACTIVE SECONDARY PROGRESSIVE MS
(NA-SPMS)
* TIZIANA LIFE SCIENCES LTD - PHASE 2 TRIAL SCREENING FOR
NA-SPMS
TO BEGIN IN NOVEMBER 2023
* TIZIANA LIFE SCIENCES : FORALUMAB TO ADVANCE INTO PHASE 2
HUMAN
CLINICAL TRIALS USING WORLD'S ONLY FULLY HUMAN INTRANASAL
ANTI-CD3 MONOCLONAL ANTIBODY
Source text for Eikon: ID:nGNX1lsBsL
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis